Influenza pandemic preparedness
Influenza pandemics, whether mild, moderate or severe, affect a large proportion of the population and require a multisectoral response over several months or even years. For this reason, countries develop plans describing their strategies for responding to a pandemic supported by operational plans at national and subnational levels.
Influenza season 2010/11 – Norway’s risk assessment and revisited vaccine recommendationsArchived
An important conclusion from this process is that the current situation, with B viruses dominating (80%), is likely to continue through the season.
ECDC – VAESCO investigation into narcolepsyArchived
This initiative was taken following the indication of a potential association between the 2009 pandemic influenza A(H1N1) monvalent vaccine and the occurrence of narcolepsy following reports, especially in children from Finland and Sweden.
Reports of cases of narcolepsy and cataplexy in children and adolescents in Finland, Iceland, and SwedenArchived
In February 2011, ECDC published a report concerning a rise in narcolepsy in children and adolescents in some northern countries.
Influenza vaccine: selection of strains to be included in the seasonal vaccine for the Northern Hemisphere 2011-2012 – Early indications of seasonal vaccine effectiveness in EuropeArchived
This recommendation for the Northern Hemisphere is the same as for the season 2010-2011 and for the Southern Hemisphere season.
Swedish MPA publishes interim results of a cohort study assessing the risk of narcolepsy after vaccination with Pandemic influenza vaccine Pandemrix®Archived
A four-fold increased incidence of narcolepsy in vaccinated children/adolescents compared to unvaccinated children was observed in this register-based cohort study.
Narcolepsy following pandemic influenza A H1N1 2009 vaccination - ECDC update: the European Medicines Agency interim measures for PandemrixArchived
In late March, 2011 ECDC reported that the Swedish Medical Product Agency published preliminary results from an on-going cohort study involving 5.3 million people, where 67% of children and adolescents and 51.0% of adults were vaccinated with Pandemrix.
European Medicines Agency (EMA) 2009 Influenza Pandemic EvaluationArchived
The European Medicines Agency (EMA) was key in the Europe during the 2009 pandemic concerning the authorisation and the benefit – risk assessment of the novel pandemic vaccines.
Case inventory study from Sweden concerning association of Pandemrix vaccination and reports of narcolepsy with cataplexy in children and adolescentsArchived
ECDC has previously summarised information concerning the appearance of narcolepsy following the use of a specific pandemic vaccine (Pandemrix®) in children and adolescents in three European Countries.
EMA's Committee for Medicinal Products for Human Use (CHMP) issues opinion on narcolepsy and vaccination with Pandemrix®Archived
On 21 July 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued its opinion on the review of Pandemrix® and reports on narcolepsy. The CHMP recommended that in persons under 20 years of age Pandemrix® may only be used if the recommended seasonal trivalent influenza vaccine is not available and if immunisation against H1N1 is still needed (e.g. in persons at risk of the complications of infection).